Work

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.3059

Authors: Lee S. Rosen, Francisco Robert, Daniela Matei, Jonathan Wade Goldman, David S. Mendelson, E. Gabriela Chiorean, Robert Matthew Strother, Ben K. Seon, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Michael S. Gordon

Institutions: University of California, Los Angeles, University of Alabama at Birmingham, Indiana University School of Medicine, Pinnacle Oncology Hematology, Roswell Park Comprehensive Cancer Center, Tracon Pharmaceuticals (United States)

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2470159777

Cites:

Cited by: 4

Related to: 10